Series B1 September 2025

Cyted Health raises £33m Series B funding led by EQT Life Sciences to scale US expansion

The financing round was led by EQT Life Sciences alongside co-leads Advent Life Sciences and British Business Bank.

£33.0MSeries B

Cyted Health is a gastrointestinal molecular diagnostics company that provides minimally invasive cell collection and biomarker testing for esophageal conditions. Its technology is deployed across the UK and expanding into the US market.

Cyted Health has secured £33m in Series B funding led by EQT Life Sciences. The round was co-led by Advent Life Sciences and the British Business Bank, with further participation from existing backers Morningside and BGF.

The capital will be deployed to accelerate commercial expansion across the United States, scale operations in the UK, and broaden the company portfolio of advanced diagnostic tests. Cyted operates a diagnostics platform anchored by its EndoSign device and molecular biomarker testing.

The financing arrives alongside the ongoing DETECT-ME clinical validation study in the United States, which commenced earlier in the year. The company has previously completed over 35,000 tests within the National Health Service.

From the founder

"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."

Marcel Gehrung

CEO and Co-founder at Cyted Health

Investor perspective

"Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide. Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio."

Bruno Holthof

Partner, EQT Life Sciences